CA3019596A1 - Array-based peptide libraries for therapeutic antibody characterization - Google Patents

Array-based peptide libraries for therapeutic antibody characterization Download PDF

Info

Publication number
CA3019596A1
CA3019596A1 CA3019596A CA3019596A CA3019596A1 CA 3019596 A1 CA3019596 A1 CA 3019596A1 CA 3019596 A CA3019596 A CA 3019596A CA 3019596 A CA3019596 A CA 3019596A CA 3019596 A1 CA3019596 A1 CA 3019596A1
Authority
CA
Canada
Prior art keywords
peptides
antibody
library
competitor
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3019596A
Other languages
English (en)
French (fr)
Inventor
Matthew Greving
David Smith
Gaurav Saini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HealthTell Inc
Original Assignee
HealthTell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HealthTell Inc filed Critical HealthTell Inc
Publication of CA3019596A1 publication Critical patent/CA3019596A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • C40B50/18—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support using a particular method of attachment to the solid support
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623—Immobilisation or binding
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00675—In-situ synthesis on the substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00709—Type of synthesis
    • B01J2219/00711—Light-directed synthesis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Structural Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
CA3019596A 2016-04-01 2017-03-31 Array-based peptide libraries for therapeutic antibody characterization Abandoned CA3019596A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662317353P 2016-04-01 2016-04-01
US62/317,353 2016-04-01
US201762472504P 2017-03-16 2017-03-16
US62/472,504 2017-03-16
PCT/US2017/025546 WO2017173365A1 (en) 2016-04-01 2017-03-31 Array-based peptide libraries for therapeutic antibody characterization

Publications (1)

Publication Number Publication Date
CA3019596A1 true CA3019596A1 (en) 2017-10-05

Family

ID=59966524

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3019596A Abandoned CA3019596A1 (en) 2016-04-01 2017-03-31 Array-based peptide libraries for therapeutic antibody characterization

Country Status (9)

Country Link
US (3) US20190113522A1 (https=)
EP (1) EP3436825A4 (https=)
JP (1) JP2019520421A (https=)
KR (1) KR20180136464A (https=)
CN (2) CN115094523A (https=)
AU (1) AU2017240164A1 (https=)
CA (1) CA3019596A1 (https=)
SG (1) SG11201808628PA (https=)
WO (1) WO2017173365A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2430574A1 (en) 2009-04-30 2012-03-21 Patientslikeme, Inc. Systems and methods for encouragement of data submission in online communities
AU2017359450A1 (en) 2016-11-09 2019-05-30 HealthTell, Inc. Coatings with tunable amine density
WO2018089554A1 (en) 2016-11-09 2018-05-17 Healthtell Inc. Pre-assembled, protected, chemically stable, chemoselective linkers
WO2019055879A2 (en) 2017-09-15 2019-03-21 PatientsLikeMe Inc. SYSTEMS AND METHODS FOR COLLECTING AND ANALYZING COMPLETE MEDICAL INFORMATION
TW201923091A (zh) * 2017-10-09 2019-06-16 美商健康堤爾股份有限公司 用於定向免疫反應的免疫原及由此產生之抗體
WO2019074940A1 (en) * 2017-10-09 2019-04-18 Healthtell Inc. INTEGRATED PLATFORM FOR SELECTING LIAISON PARTNERS BASED ON TARGET AND SPECIFICITY INFORMATION
WO2019157362A1 (en) * 2018-02-09 2019-08-15 Healthtell Inc. Array-based cyclic peptide libraries
US11894139B1 (en) 2018-12-03 2024-02-06 Patientslikeme Llc Disease spectrum classification
CN115116543B (zh) * 2022-04-18 2025-08-05 腾讯科技（深圳）有限公司 抗原抗体结合位点确定方法、装置、设备和存储介质

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
KR100529600B1 (ko) * 2003-01-23 2005-11-22 정만길 디옥소아테미시닌 유사체, 그의 제조방법 및 그를포함하는 항암제
US8217154B2 (en) * 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
CN104379821A (zh) * 2012-03-31 2015-02-25 艾比玛特生物医药（上海）有限公司 肽和抗体文库及其应用
RU2684595C2 (ru) * 2012-07-04 2019-04-09 Ф.Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты антиген-антитело
WO2014062981A1 (en) * 2012-10-17 2014-04-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University In situ chemical patterning
SG11201600853UA (en) * 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
US20170212101A1 (en) * 2014-07-18 2017-07-27 Cdi Laboratories, Inc. Methods and compositions to identify, quantify, and characterize target analytes and binding moieties

Also Published As

Publication number Publication date
SG11201808628PA (en) 2018-10-30
JP2019520421A (ja) 2019-07-18
AU2017240164A1 (en) 2018-11-15
WO2017173365A1 (en) 2017-10-05
US20240159770A1 (en) 2024-05-16
EP3436825A1 (en) 2019-02-06
CN109313184A (zh) 2019-02-05
US20190113522A1 (en) 2019-04-18
US20240077492A1 (en) 2024-03-07
EP3436825A4 (en) 2020-03-18
CN115094523A (zh) 2022-09-23
KR20180136464A (ko) 2018-12-24

Similar Documents

Publication Publication Date Title
US20240159770A1 (en) Computer-based methods of designing patterned mask
Ledsgaard et al. Antibody cross-reactivity in antivenom research
Drake et al. Characterizing high-affinity antigen/antibody complexes by kinetic-and equilibrium-based methods
Sun et al. Recent advances in microarray technologies for proteomics
Hansen et al. Identification and mapping of linear antibody epitopes in human serum albumin using high-density peptide arrays
US20180259510A1 (en) Non-covalent patterned chemical features and use thereof in maldi-based quality control
Xu et al. Application of computer-assisted molecular modeling for immunoassay of low molecular weight food contaminants: A review
AU2018225170A1 (en) Methods for screening infections
US11371990B2 (en) Methods for identifying candidate biomarkers
JP2020524275A (ja) 鑑別診断のための免疫シグネチャー
JP2016540212A (ja) 多価多重特異性分子の生物学的活性を決定するためのｓｐｒベースの架橋アッセイ
Salimi-Moosavi et al. Rapid affinity measurement of protein–protein interactions in a microfluidic platform
Drake et al. Biophysical considerations for development of antibody-based therapeutics
US12493033B2 (en) Method for detecting bi-specific antibody complex
US20250341517A1 (en) Switching peptide, immunoassay device comprising same, and immunoassay method using same
De Leon et al. B cell epitope mapping: The journey to better vaccines and therapeutic antibodies
Greiff et al. A minimal model of peptide binding predicts ensemble properties of serum antibodies
Wu et al. De novo design of epitope-specific antibodies via a structure-driven computational workflow
Olaleye et al. Determination of binding sites on trastuzumab and pertuzumab to selective affimers using hydrogen–deuterium exchange mass spectrometry
TW201922771A (zh) 用於源自目標及特異性訊息之結合配偶體選擇的整合平台
Wang et al. Application of N-terminal site-specific biotin and digoxigenin conjugates to clinical anti-drug antibody assay development
WO2025102085A1 (en) Methods and systems for detecting one or more analytes associated with one or more autoimmune diseases
Kibat et al. Utilisation of antibody microarrays for the selection of specific and informative antibodies from recombinant library binders of unknown quality
HK40004261A (en) Array-based peptide libraries for therapeutic antibody characterization
Joubbi et al. Improving Antibody-Antigen Interaction Prediction Through Flexibility with ESMFold.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221003